Financing ·
Innate Pharma S.A. completed a private placement of 17,647,059 new ordinary shares at €1.70 per share on August 18…
IPHYFInnate Pharma SA
Innate Pharma S.A. completed a private placement of 17,647,059 new ordinary shares at €1.70 per share on August 18, 2026, raising approximately €30.0 million in gross proceeds and €27.6 million net after expenses. The capital increase was executed without preferential subscription rights for existing shareholders pursuant to shareholder resolutions from May 21, 2026. Proceeds will primarily fund the clinical development of IPH4502 and advance preclinical ADC portfolio candidates. Innate Pharma S.A. operates in the biotechnology industry, focusing on the discovery and development of immunotherapies for cancer.